

Electronic Supplementary Material

Simoons and Seldenrijk et al., Drug Safety.

Full list of all retrieved publications from the literature review. Because evidence was insufficient, additional expert opinion was used to formulate the consensus recommendations.

- [1] Aichhorn W, Whitworth AB, Weiss EM, Hinterhuber H, Marksteiner J. Differences between men and women in side effects of second-generation antipsychotics. *Nervenarzt* 2007;78:45-52.
- [2] Al-Abri SA, Woodburn C, Olson KR, Kearney TE. Ventricular dysrhythmias associated with poisoning and drug overdose: a 10-year review of statewide poison control center data from California. *Am J Cardiovasc Drugs* 2015;15:43-50.
- [3] Alvarez W, Jr, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. *Pharmacotherapy* 2003;23:754-771.
- [4] Ames D, Camm J, Cook P, Falkai P, Gury C, Hurley R et al. Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group. *Encephale* 2002;28:552-562.
- [5] Astrom-Lilja C, Odeberg JM, Ekman E, Hagg S. Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database. *Pharmacoepidemiol Drug Saf* 2008;17:587-592.
- [6] Auquier P, Lancon C, Rouillon F, Lader M, Holmes C. Mortality in schizophrenia. *Pharmacoepidemiol Drug Saf* 2006;15:873-879.
- [7] Bailey B, Buckley NA, Amre DK. A meta-analysis of prognostic indicators to predict seizures, arrhythmias or death after tricyclic antidepressant overdose. *J Toxicol Clin Toxicol* 2004;42:877-888.
- [8] Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. *Psychosomatics* 2013;54:1-13.
- [9] Brewer TL, Collins M. A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. *J Spec Pediatr Nurs* 2014;19:119-126.
- [10] Buckley NA, Faunce TA. 'Atypical' antidepressants in overdose: clinical considerations with respect to safety. *Drug Saf* 2003;26:539-551.
- [11] Bullock R. Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. *Curr Med Res Opin* 2005;21:1-10.
- [12] Camm AJ, Karayal ON, Meltzer H, Kolluri S, O'Gorman C, Miceli J et al. Ziprasidone and the corrected QT interval: a comprehensive summary of clinical data. *CNS Drugs* 2012;26:351-365.
- [13] Carreiro SV, Martins RR, De Carvalho A. Psychotropic drugs and sudden death. *Acta Med Port* 2006;19:151-164.
- [14] Castillo Sanchez M, Fabregas Escurriola M, Berge Baquero D, Goday Arno A, Valles Callol JA. Psychosis, cardiovascular risk and associated mortality: are we on the right track? *Clin Investig Arterioscler* 2014;26:23-32.
- [15] Chung AK, Chua SE. Effects on prolongation of Bazett's corrected QT interval of seven second-generation antipsychotics in the treatment of schizophrenia: a meta-analysis. *J Psychopharmacol* 2011;25:646-666.
- [16] Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10-year, retrospective cohort study. *J Clin Psychiatry* 2009;70:122-129.
- [17] Cubeddu LX. QT prolongation and fatal arrhythmias: a review of clinical implications and effects of drugs. *Am J Ther* 2003;10:452-457.
- [18] de Groot MH, van Campen JP, Moek MA, Tulner LR, Beijnen JH, Lamoth CJ. The effects of fall-risk-increasing drugs on postural control: a literature review. *Drugs Aging* 2013;30:901-920.

- [19] De Hert M, Detraux J, van Winkel R, Yu W, Correll CU. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. *Nat Rev Endocrinol* 2011;8:114-126.
- [20] De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview. *Drug Saf* 2002;25:263-286.
- [21] De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. *Eur J Clin Pharmacol* 2000;56:1-18.
- [22] Del Rosario ME, Weachter R, Flaker GC. Drug-induced QT prolongation and sudden death. *Mo Med* 2010;107:53-58.
- [23] Dorado P, Berecz R, Penas-Lledo EM, Llerena A. Antipsychotic drugs and QTc prolongation: the potential role of CYP2D6 genetic polymorphism. *Expert Opin Drug Metab Toxicol* 2007;3:9-19.
- [24] Fanoë S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. *Eur Heart J* 2014;35:1306-1315.
- [25] Fazekas T, Liskai G. Clinical proarrhythmias induced by anti-arrhythmic drugs, non-cardiovascular agents and implantable cardioverter-defibrillators. *Orv Hetil* 2002;143:61-69.
- [26] Fazekas T, Liskai G. Proarrhythmic (torsadogenic) effects of QT-prolonging non-antiarrhythmic drugs. *Orv Hetil* 2005;146:451-460.
- [27] Foulke GE, Albertson TE, Walby WF. Tricyclic antidepressant overdose: emergency department findings as predictors of clinical course. *Am J Emerg Med* 1986;4:496-500.
- [28] Freeman MP, Freeman SA. Lithium: clinical considerations in internal medicine. *Am J Med* 2006;119:478-481.
- [29] Frimas V, Roberge C, Perroux D, Dauvillier JM. Cardiological monitoring of antipsychotic-treated patients: evaluation and evolution of a hospital protocol. *Encephale* 2008;34:467-476.
- [30] Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. *Ann Pharmacother* 2013;47:1330-1341.
- [31] Girardin FR, Gex-Fabry M, Berney P, Shah D, Gaspoz JM, Dayer P. Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. *Am J Psychiatry* 2013;170:1468-1476.
- [32] Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs. *J Clin Psychiatry* 2002;63 Suppl 9:12-17.
- [33] Glassman AH, Bigger JT, Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. *Am J Psychiatry* 2001;158:1774-1782.
- [34] Greco KE, Tune LE, Brown FW, Van Horn WA. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. *J Clin Psychiatry* 2005;66:928-929.
- [35] Groleau G, Jotte R, Barish R. The electrocardiographic manifestations of cyclic antidepressant therapy and overdose: a review. *J Emerg Med* 1990;8:597-605.
- [36] Haas SJ, Hill R, Krum H, Liew D, Tonkin A, Demos L et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. *Drug Saf* 2007;30:47-57.
- [37] Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics : differential risk and clinical implications. *CNS Drugs* 2007;21:911-936.
- [38] Hale AS. A review of the safety and tolerability of sertindole. *Int Clin Psychopharmacol* 1998;13 Suppl 3:S65-70.

- [39] Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. *CNS Drugs* 2014;28:887-920.
- [40] Hasnain M, Vieweg WV, Howland RH, Kogut C, Breden Crouse EL, Koneru JN et al. Quetiapine and the need for a thorough QT/QTc study. *J Clin Psychopharmacol* 2014;34:3-6.
- [41] Hays JT. Tobacco dependence treatment in patients with heart and lung disease: implications for intervention and review of pharmacological therapy. *J Cardiopulm Rehabil* 2000;20:215-223.
- [42] Herrmann N, Lanctot KL. Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned? *Drug Saf* 2006;29:833-843.
- [43] Ho JM, Gomes T, Straus SE, Austin PC, Mamdani M, Juurlink DN. Adverse cardiac events in older patients receiving venlafaxine: a population-based study. *J Clin Psychiatry* 2014;75:e552-8.
- [44] Howland RH. Psychiatric medications and sudden cardiac death: putting the risk in perspective. *J Psychosoc Nurs Ment Health Serv* 2015;53:23-25.
- [45] Howland RH. The comparative cardiac effects of haloperidol and quetiapine: parsing a review. *J Psychosoc Nurs Ment Health Serv* 2014;52:23-26.
- [46] Joy JP, Coulter CV, Duffull SB, Isbister GK. Prediction of torsade de pointes from the QT interval: analysis of a case series of amisulpride overdoses. *Clin Pharmacol Ther* 2011;90:243-245.
- [47] Kao LW, Kirk MA, Evers SJ, Rosenfeld SH. Droperidol, QT prolongation, and sudden death: what is the evidence? *Ann Emerg Med* 2003;41:546-558.
- [48] Karamatskos E, Lambert M, Mulert C, Naber D. Drug safety and efficacy evaluation of sertindole for schizophrenia. *Expert Opin Drug Saf* 2012;11:1047-1062.
- [49] Kelly DL, Love RC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. *Psychopharmacol Bull* 2001;35:66-79.
- [50] Kireyev D, Arkhipov MV, Zador ST, Paris JA, Boden WE. Clinical utility of aVR-The neglected electrocardiographic lead. *Ann Noninvasive Electrocardiol* 2010;15:175-180.
- [51] Koegelenberg CF, Joubert ZJ, Irusen EM. Tricyclic antidepressant overdose necessitating ICU admission. *S Afr Med J* 2012;102:293-294.
- [52] Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. *Molecules* 2015;20:2208-2228.
- [53] Koponen H, Alaraisanen A, Saari K, Pelkonen O, Huikuri H, Raatikainen MJ et al. Schizophrenia and sudden cardiac death: a review. *Nord J Psychiatry* 2008;62:342-345.
- [54] Kovacs D, Arora R. Cardiovascular effects of psychotropic drugs. *Am J Ther* 2008;15:474-483.
- [55] Kurth J, Maguire G. Pediatric case report of quetiapine overdose and QTc prolongation. *Ann Clin Psychiatry* 2004;16:229-231.
- [56] Lange-Asschenfeldt C, Lederbogen F. Antidepressant therapy in coronary artery disease. *Nervenarzt* 2011;82:657-64; quiz 665-6.
- [57] Laursen TM, Munk-Olsen T, Vestergaard M. Life expectancy and cardiovascular mortality in persons with schizophrenia. *Curr Opin Psychiatry* 2012;25:83-88.
- [58] Lindstrom E, Farde L, Eberhard J, Haverkamp W. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole. *Int J Neuropsychopharmacol* 2005;8:615-629.
- [59] Lopponen P, Tetri S, Juvela S, Huhtakangas J, Saloheimo P, Bode MK et al. Association between warfarin combined with serotonin-modulating antidepressants and increased case fatality in primary intracerebral hemorrhage: a population-based study. *J Neurosurg* 2014;120:1358-1363.
- [60] Mackin P. Cardiac side effects of psychiatric drugs. *Hum Psychopharmacol* 2008;23 Suppl 1:3-14.

- [61] Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. *Crit Care Clin* 2008;24:657-722, vii.
- [62] Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry* 2004;161:1334-1349.
- [63] Menkes DB, Knight JC. Cardiotoxicity and prescription of thioridazine in New Zealand. *Aust N Z J Psychiatry* 2002;36:492-498.
- [64] Merrill DB, Dec GW, Goff DC. Adverse cardiac effects associated with clozapine. *J Clin Psychopharmacol* 2005;25:32-41.
- [65] Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? *J Hosp Med* 2010;5:E8-16.
- [66] Meyer-Massetti C, Vaerini S, Ratz Bravo AE, Meier CR, Guglielmo BJ. Comparative safety of antipsychotics in the WHO pharmacovigilance database: the haloperidol case. *Int J Clin Pharm* 2011;33:806-814.
- [67] Mittal V, Kurup L, Williamson D, Muralee S, Tampi RR. Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. *Am J Alzheimers Dis Other Demen* 2011;26:10-28.
- [68] Mohr WK, Petti TA, Mohr BD. Adverse effects associated with physical restraint. *Can J Psychiatry* 2003;48:330-337.
- [69] Neuhut R, Lindenmayer JP, Silva R. Neuroleptic malignant syndrome in children and adolescents on atypical antipsychotic medication: a review. *J Child Adolesc Psychopharmacol* 2009;19:415-422.
- [70] Olgun H, Yildirim ZK, Karacan M, Ceviz N. Clinical, electrocardiographic, and laboratory findings in children with amitriptyline intoxication. *Pediatr Emerg Care* 2009;25:170-173.
- [71] Peter L, Dome P, Rihmer Z, Kovacs G, Faludi G. Cardiovascular disorders and depression: a review of epidemiological and possible etiological data. *Neuropsychopharmacol Hung* 2008;10:81-90.
- [72] Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. *Am J Cardiol* 2011;107:972-979.
- [73] Postema PG, Wolpert C, Amin AS, Probst V, Borggreffe M, Roden DM et al. Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). *Heart Rhythm* 2009;6:1335-1341.
- [74] Rabkin SW. Impact of Age and Sex on QT Prolongation in Patients Receiving Psychotropics. *Can J Psychiatry* 2015;60:206-214.
- [75] Raedler TJ. Cardiovascular aspects of antipsychotics. *Curr Opin Psychiatry* 2010;23:574-581.
- [76] Reingardiene D, Vilcinskaite J. QTc-prolonging drugs and the risk of sudden death. *Medicina (Kaunas)* 2007;43:347-353.
- [77] Richards JR, Schneir AB. Droperidol in the emergency department: is it safe? *J Emerg Med* 2003;24:441-447.
- [78] Sala M, Lazzaretti M, De Vidovich G, Caverzasi E, Barale F, d'Allio G et al. Electrophysiological changes of cardiac function during antidepressant treatment. *Ther Adv Cardiovasc Dis* 2009;3:29-43.
- [79] Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P et al. Drawing up guidelines for the attendance of physical health of patients with severe mental illness. *Encephale* 2009;35:330-339.
- [80] Sicouri S, Antzelevitch C. Sudden cardiac death secondary to antidepressant and antipsychotic drugs. *Expert Opin Drug Saf* 2008;7:181-194.

- [81] Singh N, Singh HK, Khan IA. Serial electrocardiographic changes as a predictor of cardiovascular toxicity in acute tricyclic antidepressant overdose. *Am J Ther* 2002;9:75-79.
- [82] Smithburger PL, Seybert AL, Armahizer MJ, Kane-Gill SL. QT prolongation in the intensive care unit: commonly used medications and the impact of drug-drug interactions. *Expert Opin Drug Saf* 2010;9:699-712.
- [83] Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH et al. Antipsychotics and the risk of sudden cardiac death. *Arch Intern Med* 2004;164:1293-1297.
- [84] Tamargo J. Drug-induced torsade de pointes: from molecular biology to bedside. *Jpn J Pharmacol* 2000;83:1-19.
- [85] Taylor DM. Antipsychotics and QT prolongation. *Acta Psychiatr Scand* 2003;107:85-95.
- [86] Titier K, Canal M, Deridet E, Abouelfath A, Gromb S, Molimard M et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: comparison with their ability to induce arrhythmia and sudden death in clinical practice. *Toxicol Appl Pharmacol* 2004;199:52-60.
- [87] Vieweg WV. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs. *J Clin Psychiatry* 2002;63 Suppl 9:18-24.
- [88] Vieweg WV, Hasnain M, Hancox JC, Baranchuk A, Digby GC, Kogut C et al. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports. *Psychopharmacology (Berl)* 2013;228:515-524.
- [89] Vieweg WV, Hasnain M, Howland RH, Hetteema JM, Kogut C, Wood MA et al. Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? *Am J Med* 2012;125:859-868.
- [90] Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. *Drugs Aging* 2009;26:997-1012.
- [91] Viskin S, Justo D, Halkin A, Zeltser D. Long QT syndrome caused by noncardiac drugs. *Prog Cardiovasc Dis* 2003;45:415-427.
- [92] Waring WS, Good AM, Bateman DN. Lack of significant toxicity after mirtazapine overdose: a five-year review of cases admitted to a regional toxicology unit. *Clin Toxicol (Phila)* 2007;45:45-50.
- [93] Warner B, Hoffmann P. Investigation of the potential of clozapine to cause torsade de pointes. *Adverse Drug React Toxicol Rev* 2002;21:189-203.
- [94] Wilens TE, Biederman J, Baldessarini RJ, Geller B, Schleifer D, Spencer TJ et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. *J Am Acad Child Adolesc Psychiatry* 1996;35:1491-1501.
- [95] Wilens TE, Stern TA, O'Gara PT. Adverse cardiac effects of combined neuroleptic ingestion and tricyclic antidepressant overdose. *J Clin Psychopharmacol* 1990;10:51-54.
- [96] Wobrock T, Schwaab B, Bohm M, Schafers HJ, Wanke K, Supprian T. Pharmacotherapeutical approaches to insomnia patients with cardiac diseases and after heart transplantation. *Z Kardiol* 2001;90:717-728.
- [97] Xue F, Strombom I, Turnbull B, Zhu S, Seeger J. Treatment with duloxetine in adults and the incidence of cardiovascular events. *J Clin Psychopharmacol* 2012;32:23-30.
- [98] Zeltser D, Justo D, Halkin A, Prokhorov V, Heller K, Viskin S. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. *Medicine (Baltimore)* 2003;82:282-290.
- [99] Zemrak WR, Kenna GA. Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. *Am J Health Syst Pharm* 2008;65:1029-1038.

[100] More evidence on risks of antipsychotics in adults. Commentaries provide advice about putting the results in perspective. *Harv Ment Health Lett* 2009;25:6.

Electronic Supplementary Material to:

Limited evidence for Risk factors for proarrhythmia and sudden cardiac death in patients using antidepressants: Dutch consensus on ECG monitoring.

Drug Safety

Mirjam, Simoons^{a,b,c}, Adrie, Seldenrijk^{b,d*}, Hans, Mulder^{a,e}, Tom, Birkenhäger^{f,g}, Mascha, Groothedde-Kuyvenhoven^h, Rob, Kokⁱ, Cornelis, Kramers^j, Wim, Verbeek^{k,l}, Mirjam, Westra^b, Eric van Roon^{c,m}, Roberto, Bakker^{n,o#}, Henricus, Ruhé^{b,p,q#}*

^a *Wilhelmina Hospital Assen, Department of Clinical Pharmacy, Assen, The Netherlands*

^b *University of Groningen, University Medical Centre Groningen, Department of Psychiatry, Interdisciplinary Centre for Psychopathology and Emotion regulation, Groningen, The Netherlands*

^c *University of Groningen, Department of Pharmacy, Unit of Pharmacotherapy, -Epidemiology & -Economics, Groningen, The Netherlands*

^d *GGZ InGeest, Department of Research & Innovation, Amsterdam, The Netherlands*

^e *Psychiatric Hospital GGZ Drenthe, Assen, The Netherlands*

^f *Erasmus Medical Centre, Department of Psychiatry, Rotterdam, The Netherlands*

^g *Collaborative Antwerp Psychiatric Research Institute (CAPRI), University of Antwerp, Belgium*

^h *Deventer Hospital, Department of Clinical Pharmacy, Deventer, The Netherlands*

ⁱ *Parnassia Psychiatric Institute, Department of Old Age Psychiatry, The Hague, The Netherlands*

^j *Radboudumc, Department of Internal Medicine, Nijmegen, The Netherlands*

^k *Vincent van Gogh Institute for Psychiatry, ADHD and Autism Circuit, Venray, the Netherlands*

^l *Radboudumc, Department of Pharmacology and Toxicology, Nijmegen, The Netherlands*

^m *Medical Centre Leeuwarden, Department of Clinical Pharmacy and Clinical Pharmacology, Leeuwarden, The Netherlands*

ⁿ *Psychiatric Centre GGz Centraal, Amersfoort, The Netherlands.*

^o *Maastricht University Medical Centre, Department of Psychiatry and Psychology, South Limburg Mental Health and Teaching Network, Maastricht, The Netherlands.*

^p *Warneford Hospital, University of Oxford, Department of Psychiatry, United Kingdom*

^q *Radboudumc, Department of Psychiatry, Nijmegen, The Netherlands*

** These authors share first authorship*

These authors share senior authorship

Corresponding author: Henricus Ruhé, MD, PhD, e-mail: h.q.ruhe@umcg.nl.